Alnylam Assist™: We’re Here to Help Your Patients

Call Kevin:

1-833-256-2748

Monday - Friday, 8am - 6pm ET

Options for Getting Started

In order to make the process convenient for your patients, Alnylam Assist™ provides 3 separate options for initiating and completing the Start Form.

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Complete and submit the electronic Start
Form with your patient

Get Started

Alnylam assist® Start Form - To Print and Fax

Print, complete with your patient, and fax
the Start Form to 1-833-256-2747

Download

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

Fill out your sections of the Start Form
and email to patient to complete
via DocuSign

Begin Start Form

DocuSign Instructions ›

What services does Alnylam Assist™ offer?

Alnylam Assist™ provides a suite of support and services to personalize your patient treatment experience ›

Alnylam Assist® - Questions Icon

Find answers to other

Frequently Asked Questions ›

HCP triangle

IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most common adverse reaction that occurred in patients treated with OXLUMO® (lumasiran) was injection site reaction (38%). Symptoms included erythema, pain, pruritus, and swelling.

Pregnancy and Lactation

No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.